Yumab spinoff Corat to develop COVID-19 drug
June 17, 2020 -- Yumab has announced that the first financing round of its spinoff Corat Therapeutics will be used to advance the development of COVID-19 antibody drug candidates.
Immunomic Therapeutics inks license deal with Ichor
June 16, 2020 -- Immunomic Therapeutics (ITI) has signed a licensing agreement with Ichor Medical Systems to support the development of its ITI-1001 investigational plasmid DNA vaccine therapy.
Saiba selects AGC to manufacture COVID-19 vaccine
June 16, 2020 -- Contract development and manufacturing organization AGC Biologics said it will be manufacturing a SARS-CoV-2 vaccine for Swiss biotechnology firm Saiba.
Genprex expands gene therapy manufacturing
June 16, 2020 -- Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.
Atum, Phylex accelerate universal SARS coronavirus vaccine
June 15, 2020 -- Atum and Phylex BioSciences will collaborate to advance research toward creating a universal vaccine effective against pathogenic coronaviruses, including the novel coronavirus SARS-CoV-2.
Ligand expands oncology drug discovery with Servier
June 15, 2020 -- Ligand Pharmaceuticals subsidiary Vernalis Research has expanded its oncology drug discovery collaboration with French pharmaceutical company Servier.
FDA revokes EUA for chloroquine, hydroxychloroquine
June 15, 2020 -- The U.S. Food and Drug Administration (FDA) on June 15 revoked the emergency use authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate for patients with COVID-19.
Immunic begins phase II immunotherapy for COVID-19
June 15, 2020 -- Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.
Lilly begins phase III trial for COVID-19 therapy
June 15, 2020 -- Eli Lilly has enrolled patients in a phase III study to evaluate the efficacy and safety of baricitinib in hospitalized adults with COVID-19.
Integral Molecular aids with safety testing of COVID-19 antibodies
June 12, 2020 -- Integral Molecular is applying its membrane proteome array technology for antibody specificity profiling to accelerate development of SARS-CoV-2 therapeutic antibodies.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter